Comparative Pharmacology
Head-to-head clinical analysis: INCIVEK versus PENCICLOVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCIVEK versus PENCICLOVIR.
INCIVEK vs PENCICLOVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
Penciclovir is a nucleoside analog that inhibits viral DNA polymerase. It is phosphorylated by viral thymidine kinase to penciclovir triphosphate, which competitively inhibits viral DNA polymerase and terminates DNA chain elongation.
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
Topical: Apply 1% cream every 2 hours while awake (approximately 9 times/day) for 4 days. Oral: 500 mg twice daily for 5 days.
None Documented
None Documented
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
Terminal half-life: 2.0–2.5 hours (healthy adults); prolonged to ~9–10 hours in renal impairment (CrCl <30 mL/min); clinical context: dosing interval adjusted based on renal function.
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Renal excretion: >70% as unchanged penciclovir via glomerular filtration and tubular secretion.
Category C
Category A/B
Antiviral
Antiviral